Warnings and precautions1

Orthostatic Hypotension:

Instruct patients to sit or lie down if symptoms develop after dose administration.

Hypercalcemia:

Avoid use in patients with pre-existing hypercalcemia and those known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism.

Hypercalciuria and Urolithiasis:

Monitor urine calcium if pre-existing hypercalciuria or active urolithiasis are suspected.

Immunogenicity:

As with all therapeutic proteins, there is potential for immunogenicity. Antibody formation did not appear
to have any clinically significant impact on safety or efficacy endpoints, including BMD response, fracture reduction, immune-related hypersensitivity or allergic reactions, or other adverse events.

Reference: 1. TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.   All rights reserved.    08/17.   ABLSC-US-01042

This site is intended for HCPs in the United States.
TYMLOS is a trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.
All rights reserved. 08/17.
ABLSC-US-01042